High-throughput generation and engineering of recombinant human antibodies.
about
Basonuclins 1 and 2, whose genes share a common origin, are proteins with widely different properties and functionsDelivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierContinuous microfluidic assortment of interactive ligands (CMAIL).The testosterone binding mechanism of an antibody derived from a naïve human scFv libraryCurrent and developing technologies for monitoring agents of bioterrorism and biowarfare.Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F GlycoproteinRise and fall of an anti-MUC1 specific antibodyStructural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization.Functional mapping of conserved, surface-exposed charges of antibody variable domains.Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model.The use of immunoliposome for nutrient target regulation (a review).Synthetic antibody libraries focused towards peptide ligands.Isolation of human monoclonal antibodies by mammalian cell display.Acoustic microfluidic chip technology to facilitate automation of phage display selection.Automated panning and screening procedure on microplates for antibody generation from phage display libraries.Isolation and characterization of selective and potent human Fab inhibitors directed to the active-site region of the two-component NS2B-NS3 proteinase of West Nile virus.Overview on the use of therapeutic antibodies in drug discovery.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Hapten mediated display and pairing of recombinant antibodies accelerates assay assembly for biothreat countermeasuresA fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties.The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVAnti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growthHigh-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays.Large scale production of phage antibody libraries using a bioreactor.Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.Advance in phage display technology for bioanalysis.Protein-detecting microarrays: current accomplishments and requirements.The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitroHigh-Throughput IgG Conversion of Phage Displayed Fab Antibody Fragments by AmplYFast.A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies.Screening Phage-Display Antibody Libraries Using Protein Arrays.Construction of Naive and Immune Human Fab Phage-Display Library.Antibody production in Bacillus megaterium: strategies and physiological implications of scaling from microtiter plates to industrial bioreactors.
P2860
Q24670168-18ABAEFC-A55D-4B49-B441-CBC3FB4F3B50Q26801300-5F8C2AEC-6218-420F-8E45-4A180169E922Q27313736-F46411A5-1EDB-477D-8705-6A273AB4B738Q27666842-98F76BC4-E5E0-47BA-8AA0-7BACE94F78DDQ28386167-E90ABA37-2F38-4BE8-8236-00E7139D989EQ28552644-5A5E3691-1A7A-492F-8AB5-203C29F11D96Q28743508-00107E8E-8685-4ADF-AA0F-7D53A0AE3192Q30152958-15910102-B953-498C-81FC-CE756106DFDAQ30330138-529C954E-289E-484A-B056-7D86A8C91D95Q30882235-332C867B-8F9F-4F61-B705-6B01A600DEACQ31148688-3EE792CA-621B-4A1B-B89C-C8788B12A160Q33223886-AD13D445-4AC5-4B39-8F24-BF06406BBDFEQ33263078-DA73A2A9-A167-4398-80A3-8397A0D633F2Q33326776-E5F05F1D-F251-4320-8050-28468D1AA29BQ33371477-22D82C85-F1F6-40FA-9D70-8FE5563AAF45Q33380422-CC836399-CDCD-4B00-BA18-3AF054DF7911Q33410203-3179617F-0564-49B3-8585-CC5A11294F2FQ33531322-455A1819-7CAC-4CA9-A111-7A52E0CA8006Q34147273-644EB88F-1C90-469B-BE1A-F52A3C1AED9FQ34385892-915E3B3C-F731-49E4-896B-3C0B1DAC8DCCQ34476404-4E52DBAC-DE3F-46CC-A048-98A3B296158BQ34660961-20341068-6303-416F-AEB0-66208D291732Q34939533-101ECA69-EEEA-4ADF-98F5-22B0B719194EQ35060278-ECCDA038-DB0E-4A2D-A612-FAEC87D3C101Q35102677-559DA93B-A926-4193-9479-AC000547B49EQ35530400-4DB2C0FA-F991-45E6-B7B6-EF7573F8560BQ35890716-C3123A25-6DAD-4A24-BEDB-9591470BFAC5Q35984472-AA8B8696-BA81-4D1B-A0E7-D6EBA43A83DBQ36080618-79AA28AC-8E8C-45EC-980D-FED2CB63A164Q36160553-3C69367F-CB5F-45C5-B30E-E23E19A5E373Q36296240-308B2C7D-B6B0-48A9-B4D5-33BC9F544C4CQ36335874-5E3C69D2-62E4-476B-B5B6-A49C1D6CB3EFQ47425526-FF1B6A5E-6554-4706-8DA3-9796AC69C4E7Q50108553-398322CF-73B2-489F-87AC-EA7CE9910548Q51543536-4935521C-83CA-4C3F-8A93-C50577F51A78
P2860
High-throughput generation and engineering of recombinant human antibodies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
High-throughput generation and engineering of recombinant human antibodies.
@ast
High-throughput generation and engineering of recombinant human antibodies.
@en
type
label
High-throughput generation and engineering of recombinant human antibodies.
@ast
High-throughput generation and engineering of recombinant human antibodies.
@en
prefLabel
High-throughput generation and engineering of recombinant human antibodies.
@ast
High-throughput generation and engineering of recombinant human antibodies.
@en
P2093
P1476
High-throughput generation and engineering of recombinant human antibodies.
@en
P2093
E Thomassen
P356
10.1016/S0022-1759(01)00398-2
P577
2001-08-01T00:00:00Z